Remarkable antitumoral activity has been achieved in various cancer types by blocking the inhibitory T-cell receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein 1 (PD-1/PD-L1) axis [1]. This evidence concerns the gene PDCD1 and cancer.